Literature DB >> 11931802

Enhanced S-cone syndrome with subfoveal neovascularization.

Makoto Nakamura1, Yoshihiro Hotta, Chang-Hua Piao, Mineo Kondo, Hiroko Terasaki, Yozo Miyake.   

Abstract

PURPOSE: To report a case of enhanced S-cone syndrome associated with subfoveal neovascularization.
DESIGN: Observational case report.
METHODS: A 23-year-old man, who was first examined at age 9 years, was found to have enhanced S-cone syndrome by clinical, electrophysiological, and molecular genetic examinations.
RESULTS: At 9 years of age, a subfoveal neovascularization was present in his right eye and corrected visual acuity was RE: 0.15 and LE: 1.0. After he was 20 years old, cystoid changes in the macula of the left eye appeared and visual acuity, in the left eye, decreased from 1.0 to 0.02.
CONCLUSION: The clinical course of enhanced S-cone syndrome is progressive, and we suggest that the subretinal neovascularization is a phenotypic variation of enhanced S-cone syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931802     DOI: 10.1016/s0002-9394(01)01428-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  A novel mutation (Cys83Tyr) in the second zinc finger of NR2E3 in enhanced S-cone syndrome.

Authors:  Amândio Rocha-Sousa; Takaaki Hayashi; Nuno Lourenço Gomes; Susana Penas; Elisete Brandão; Paulo Rocha; Mitsuyoshi Urashima; Hisashi Yamada; Hiroshi Tsuneoka; Fernando Falcão-Reis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-20       Impact factor: 3.117

2.  Novel findings in enhanced S-cone syndrome: a case with macular retinal neovascularization and severe retinal vasculitis.

Authors:  Fatemeh Bazvand; Hasan Khojasteh; Mohammad Zarei
Journal:  Doc Ophthalmol       Date:  2019-07-10       Impact factor: 2.379

3.  In pursuit of synthetic modulators for the orphan retina-specific nuclear receptor NR2E3.

Authors:  Qiong Qin; Anna Knapinska; Nicoleta Dobri; Franck Madoux; Peter Chase; Peter Hodder; Konstantin Petrukhin
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-25       Impact factor: 2.671

4.  Enhanced S-cone syndrome with preserved macular structure and severely depressed retinal function.

Authors:  Ivan Cima; Jelka Brecelj; Maja Sustar; Frauke Coppieters; Bart P Leroy; Elfride De Baere; Marko Hawlina
Journal:  Doc Ophthalmol       Date:  2012-06-19       Impact factor: 2.379

5.  Novel clinical findings in autosomal recessive NR2E3-related retinal dystrophy.

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Andrea Sodi; Ilaria Passerini; Dario Giorgio; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-10-15       Impact factor: 3.117

6.  New truncation mutation of the NR2E3 gene in a Japanese patient with enhanced S-cone syndrome.

Authors:  Kazuki Kuniyoshi; Takaaki Hayashi; Hiroyuki Sakuramoto; Hiroshi Mishima; Hiroshi Tsuneoka; Kazushige Tsunoda; Takeshi Iwata; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2016-08-13       Impact factor: 2.447

7.  Expanded clinical spectrum of enhanced S-cone syndrome.

Authors:  Suzanne Yzer; Irene Barbazetto; Rando Allikmets; Mary J van Schooneveld; Arthur Bergen; Stephen H Tsang; Samuel G Jacobson; Lawrence A Yannuzzi
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

8.  Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome.

Authors:  G K Broadhead; J R Grigg; P McCluskey; M Korsakova; A A Chang
Journal:  Doc Ophthalmol       Date:  2016-07-16       Impact factor: 2.379

9.  Developmental or degenerative--NR2E3 gene mutations in two patients with enhanced S cone syndrome.

Authors:  Nitin Udar; Kent Small; Meenal Chalukya; Rosamaria Silva-Garcia; Michael Marmor
Journal:  Mol Vis       Date:  2011-02-17       Impact factor: 2.367

10.  MULTIMODAL EVIDENCE OF TYPE 3 NEOVASCULARIZATION IN ENHANCED S-CONE SYNDROME.

Authors:  Ramiro S Maldonado; Wadih M Zein; Catherine Cukras
Journal:  Retin Cases Brief Rep       Date:  2021-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.